Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The preventive role of hydroxychloroquine (HCQ) on coronavirus disease 2019 (COVID-19) remains unclear. The aim of this study was to examine the effects of HCQ and other immunosuppressive drugs on the incidence of COVID-19. Methods: The data were collected from the South Korea National Health Insurance Sharing-COVID-19 database. All individuals who underwent nasopharyngeal and oropharyngeal swab tests for COVID-19 from January 2020 to May 2020 are included. The association between COVID-19 risk and HCQ use was examined in a propensity score-matched population. Factors associated with COVID-19 were identified using multiple logistic regression analysis. Results: Total 8,070 patients with COVID-19 and 121,050 negative controls were included from the database. Among all participants, 381 were HCQ users. In a propensity score-matched population, the incidence of COVID-19 was 7.1% in HCQ users and 6.8% in non-users. The odds ratio (OR) for HCQ use was 1.05 with a 95% confidence interval (CI) of 0.58 to 1.89. Among the subpopulation of patients with rheumatoid arthritis (RA), 33 were diagnosed with COVID-19 and 478 were not. Use of HCQ, glucocorticoids, or other immunosuppressive drugs was not associated with COVID-19 risk, whereas abatacept use was. Chronic lung disease was an independent risk factor for COVID-19 diagnosis in patients with RA (adjusted OR, 6.07; 95% CI, 1.10 to 33.59). Conclusions: The risk of COVID-19 did not differ between HCQ users and non-users. Glucocorticoids, conventional disease- modifying antirheumatic drugs (DMARDs), and biological DMARDs other than abatacept did not increase the risk of COVID-19.
Abstract
Background/Aims: The preventive role of hydroxychloroquine (HCQ) on coronavirus disease 2019 (COVID-19) remains unclear. The aim of this study was to examine the effects of HCQ and other immunosuppressive drugs on the incidence of COVID-19. Methods: The data were collected from the South Korea National Health Insurance Sharing-COVID-19 database. All individuals who underwent nasopharyngeal and oropharyngeal swab tests for COVID-19 from January 2020 to May 2020 are included. The association between COVID-19 risk and HCQ use was examined in a propensity score-matched population. Factors associated with COVID-19 were identified using multiple logistic regression analysis. Results: Total 8,070 patients with COVID-19 and 121,050 negative controls were included from the database. Among all participants, 381 were HCQ users. In a propensity score-matched population, the incidence of COVID-19 was 7.1% in HCQ users and 6.8% in non-users. The odds ratio (OR) for HCQ use was 1.05 with a 95% confidence interval (CI) of 0.58 to 1.89. Among the subpopulation of patients with rheumatoid arthritis (RA), 33 were diagnosed with COVID-19 and 478 were not. Use of HCQ, glucocorticoids, or other immunosuppressive drugs was not associated with COVID-19 risk, whereas abatacept use was. Chronic lung disease was an independent risk factor for COVID-19 diagnosis in patients with RA (adjusted OR, 6.07; 95% CI, 1.10 to 33.59). Conclusions: The risk of COVID-19 did not differ between HCQ users and non-users. Glucocorticoids, conventional disease- modifying antirheumatic drugs (DMARDs), and biological DMARDs other than abatacept did not increase the risk of COVID-19.
참고문헌 (35)
- Yao X, "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)", Clin Infect Dis, 71, pp.732~739 (2020)
- Chen Z, "Efficacy of hydroxychloroquine in patients with COVID-19 : results of a randomized clinical trial", medRxiv 2020 Apr 10. https:, doi.org, pp.10.1101, 2020.03.22.20040758[DOI]
- Gautret P, "Hydroxychloroquine and azithromycin as a treatment of COVID-19 : results of an open-label non-randomized clinical trial", Int J Antimicrob Agents, 56, pp.105949~ (2020)
- Gianfrancesco M, "Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease : data from the COVID-19 Global Rheumatology Alliance physician-reported registry", Ann Rheum Dis, 79, pp.859~866 (2020)
- Mathian A, "Clinical course of coronavirus disease 2019(COVID-19)in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine", Ann Rheum Dis, 79, pp.837~839 (2020)
- Konig MF, "Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19", Ann Rheum Dis, 79, pp.1386~1388 (2020)
- Bozzalla Cassione E, "COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine", Ann Rheum Dis, 79, pp.1382~1383 (2020)
- Gendebien Z, "Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population : correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments", Ann Rheum Dis, 80, pp.218244~ (2021)
- Ferreira A, "Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection", J Med Virol, 93, pp.755~759 (2021)
- Boulware DR, "A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19", N Engl J Med, 383, pp.517~525 (2020)
- Geleris J, "Observational study of hydroxychloroquine in hospitalized patients with COVID-19", N Engl J Med, 382, pp.2411~2418 (2020)
- Mahevas M, "Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen : observational comparative study using routine care data", BMJ, 369, pp.m1844~ (2020)
- Tang W, "Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019 : open label, randomised controlled trial", BMJ, 369, pp.m1849~ (2020)
- Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19", N Engl J Med, 382, pp.1787~1799 (2020)
- Sheahan TP, "An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice", Sci Transl Med, 12, pp.eabb5883~ (2020)
- Gendelman O, "Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2 : insights from a large healthcare database analysis", Autoimmun Rev, 19, pp.102566~ (2020)
- 서미령, "Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic", The Korean Journal of Internal Medicine, 35(6), pp.1317~1332 (2020), 대한내과학회[DOI]
- Mi Ryoung Seo, "Recommendations for the Management of Patients With Systemic Rheumatic Diseases During the Coronavirus Disease Pandemic", 대한류마티스학회지, 27(4), pp.218~232 (2020), 대한류마티스학회[DOI]
- Haberman R, "COVID-19 in immune-mediated inflammatory diseases : case series from New York", N Engl J Med, 383, pp.85~88 (2020)
- Gartshteyn Y, "COVID-19and systemic lupus erythematosus : a case series", Lancet Rheumatol, 2, pp.e452~e454 (2020)
- Nuno L, "Clinical course, severity and mortality in a cohort of patients with COVID-19with rheumatic diseases", Ann Rheum Dis, 79, pp.1659~1661 (2020)
- Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
- Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
- Favalli EG, "Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs : what can we learn from observational data?", Arthritis Rheumatol, 72, pp.1600~1606 (2020)
- Quartuccio L, "Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules : a population-based study in the first two months of COVID-19outbreak in Italy", Joint Bone Spine, 87, pp.439~443 (2020)
- Cummings MJ, "Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City : a prospective cohort study", Lancet, 395, pp.1763~1770 (2020)
- Petrilli CM, "Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City : prospective cohort study", BMJ, 369, pp.m1966~ (2020)
- Docherty AB, "Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol : prospective observational cohort study", BMJ, 369, pp.m1985~ (2020)
- Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China", JAMA Intern Med, 180, pp.934~943 (2020)
- Wang D, "Mechanisms of lung disease development in rheumatoid arthritis", Nat Rev Rheumatol, 15, pp.581~596 (2019)
- Munster T, "Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis", Arthritis Rheum, 46, pp.1460~1469 (2002)
- Costedoat-Chalumeau N, "Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus", Arthritis Rheum, 54, pp.3284~3290 (2006)
- Memoli MJ, "Validation of the wild-type influenza A human challenge model H1N1pdMIST : an A(H1N1)pdm09 dose-finding investigational new drug study", Clin Infect Dis, 60, pp.693~702 (2015)
- Liu Y, "Viral dynamics in mild and severe cases of COVID-19", Lancet Infect Dis, 20, pp.656~657 (2020)
- He X, "Temporal dynamics in viral shedding and transmissibility of COVID-19", Nat Med, 26, pp.672~675 (2020)